Customize
Quick Links
Specialties

Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 2.0 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Agios Pharmaceuticals, Inc, and Jazz Pharmaceuticals, Inc.

AML Year in Review™: Live Webcast Around the World

Release Date: April 16, 2018
Expiration Date: April 16, 2019
Media: Internet - based

 

Activity Overview

PER Global®, LLC, the global affiliate of Physicians’ Education Resource®, LLC (PER) is pleased to present the CME-certified online activity titled “AML Year in Review™: Live Webcast Around the World.” This innovative activity is an archived version of the live-streamed interactive webcast held on March 23rd, 2018 and led by world renowned Acute Myeloid Leukemia (AML) experts: Francesco Lo Coco, MD; Laura Cicconi, MD; Harry P. Erba, MD; and Eytan M. Stein, MD.

This online activity will provide physicians with practical applications to optimize care for their patients with acute myeloid leukemia (AML). The activity will consist of an in-studio panel discussion between AML experts highlighting new findings in the biology and risk stratification of AML, recent clinical data and approvals, and future directions for clinical research. Key topics on the agenda include:

  • Biology of AML and historical perspectives on the evolution of diagnosis and treatment
  • Best practices in risk stratification and therapeutic decision making
  • Recent practice-changing data and emerging clinical strategies in AML

Join us online for AML Year in Review™: Live Webcast Around the World, which will bring conference-caliber education to the convenience of your screen!

CME/CE Activity Table of Contents

  • Setting the Stage: AML Biology and Historical Perspective
  • Best Practices to Stratify Risk and Inform Key Decisions in Management
  • New Standards of Care for Initial Management of AML
  • Assessing Recent Evidence in Relapsed/Refractory AML Settings
  • Putting it All Together and Looking to the Near Future

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a cme/ce certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a cme/ce certificate upon completion of these steps.

Target Audience

This activity is directed toward medical oncologists, oncologist/hematologists, hematologists, and nurses who treat patients with AML. Fellows, nurse practitioners, physician assistants, and other healthcare professionals involved in the management of patients with AML are also invited to participate.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  • Identify testing strategies used to stratify risk and identify mutations among patients with AML, including their findings’ impact on clinical decision making
  • Utilize recent evidence-based recommendations concerning the use of testing strategies in AML treatment settings
  • Describe results from clinical trials that evaluated current and emerging strategies in patients with AML
  • Apply novel treatment approaches in the context of real-world clinical scenarios encountered in the management of AML

Faculty, Staff, and Planners' Disclosures

Moderator

Francesco Lo Coco, MD
Ordinario di Ematologia
Dipartimento di Biomedicina e Prevenzione
Università Tor Vergata
Rome, Italy

Disclosure: Consultant: Orsenix; Speakers Bureau: Novartis, Teva

Faculty

Laura Cicconi, MD
Dipartimento di Biomedicina e Prevenzione
Università Tor Vergata
Rome, Italy
 
 

Disclosure: No relevant financial relationships with commercial interest to disclose.

Harry P. Erba, MD, PhD
Professor of Medicine
Director, UAB Hematologic Malignancy Program
The University of Alabama at Birmingham School of Medicine
Birmingham, AL
 

Disclosure: Grant/Research Support: Agios, Amgen, Astellas, Daiichi Sankyo, ImmunoGen, Janssen, Juno, Millennium/Takeda, Seattle Genetics; Consultant: Celgene, Amgen, Jazz, Daiichi Sankyo, Incyte, MacroGenics, Novartis, Ono, Settle Genetics; Speakers Bureau: Celgene, Incyte, Novartis; Other: GlycoMimetics Inc (Data and Safety Monitoring Committee), Celgene (Chair, Scientific Steering Committee, AML Registry Study)

Eytan M. Stein, MD
Assistant Attending Physician
Leukemia Service
Memorial Sloan Kettering Cancer Center
New York, NY
 

Disclosure: Grant/Research Support: Agios, Celgene; Other (Advisory Board): Celgene, Agios, Pfizer, Bayer, Novartis.

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

PER Pulse Recap™

PER Pulse Recap (1 of 3)

This live-streamed, interactive, continuing medical education (CME)‒certified webcast, AML Year in Review™: Live Webcast Around the World, was held on March 23, 2018. Expert faculty joined Francesco Lo Coco, MD, to discuss new findings in the biology and risk stratification of acute myeloid leukemia (AML), recent clinical data and approvals, and future directions for clinical research.
 
This first of 3 PER Pulse™ Recaps summarizing the online webcast focuses on best practices for stratifying risk in patients with AML and for informing key decisions in disease management. Below are some highlights from the activity featuring Dr. Lo Coco, along with Laura Cicconi, MD, Harry P. Erba, MD, PhD, and Eytan M. Stein, MD:
  • New classification schemes for AML incorporating cytogenetics, including recent changes to the World Health Organization Classification system
  • A discussion of how new findings on the biology of AML impact diagnostic procedures and what is required for proper diagnosis, including targeted mutations FLT3 and IDH and the importance of the optimal timing of genetic testing in disease course
  • An overview and interpretation of the genetic abnormality updates in the 2017 European LeukemiaNet Risk Stratification guidelines, including consolidation of the Intermediate 1 and Intermediate 2 categories and the need for more research on risk stratification for rare AML subtypes
“The way you initially characterize these patients [with AML] not only affects the way we treat them but also the way we evaluate their response. A more comprehensive and up-to-date characterization would include a well-performed immunophenotype. …I strongly believe this is the way to go.”
 — Francesco Lo Coco, MD

PER Pulse Recap (2 of 3)

As a follow-up to this live-streamed, interactive, continuing medical education (CME)‒certified webcast, AML Year in Review™: Live Webcast Around the World, held on March 23, 2018, this second of 3 PER Pulse™ Recaps summarizing the online program focuses on new standards of care for the initial treatment of acute myeloid leukemia (AML), including targeted and cytotoxic therapies. Below are some highlights from the activity featuring Dr. Francesco Lo Coco, along with Laura Cicconi, MD, Harry P. Erba, MD, PhD, and Eytan M. Stein, MD:
  • An overview of treatment paradigms for newly diagnosed AML prior to the advent of targeted therapy and the evolution of AML treatment from a one-size-fits-all approach to modern targeted therapeutic strategies (eg, FLT3 inhibition)
  • A recap of the C10603/RATIFY trial, data from which supported the approval of midostaurin in combination with chemotherapy for patients with newly diagnosed, FLT3-positive AML
  • Discussion of the CD33-directed antibody-drug conjugate gemtuzumab ozogamicin (GO), recently approved for first relapse of AML
  • Critical analysis of important data, including those from a meta-analysis of GO with AML induction therapy, the phase III ALFA-0701 study of GO versus standard treatment in adult patients with de novo AML, and the phase III AML-19 trial of GO compared with best supportive care as first-line therapy in patients with AML unsuitable for chemotherapy
  • Expert commentary on new cytotoxic therapies for AML, including liposomal daunorubicin/cytarabine (CPX-351) and associated clinical trials in patients with newly diagnosed AML that yielded promising results
“Liposomal daunorubicin/cytarabine [CPX-351] was based on quite a bit of preclinical data suggesting that the way we give these two drugs in combination may be critically important. …If you vary the ratio of daunorubicin to cytarabine from high to low, there seems to be this sweet spot where the molar ratio of 1:5 of daunorubicin to cytarabine enhances cell kill and synergy.”
 — Harry P. Erba, MD, PhD

PER Pulse Recap (3 of 3)

As a follow-up to this live-streamed, interactive, continuing medical education (CME)‒certified webcast, AML Year in Review™: Live Webcast Around the World, held on March 23, 2018, this third of 3 PER Pulse™ Recaps summarizing the online program focuses on recent evidence in the treatment of relapsed/refractory acute myeloid leukemia (AML) with isocitrate dehydrogenase (IDH) inhibitors. Below are some highlights from the activity featuring Dr. Francesco Lo Coco, along with Laura Cicconi, MD, Harry P. Erba, MD, PhD, and Eytan M. Stein, MD:
  • An overview of the biologic rationale for the therapeutic inhibition of IDH in AML, specific IDH inhibitors (eg, enasidenib, ivosidenib)
  • Practical guidance for use of IDH inhibitors that considers clinical trial data demonstrating a robust rate of complete remission and minimal toxicity with single-agent enasidenib for the treatment of IDH2-mutated, relapsed/refractory AML and supported the approval of enasidenib in this setting
  • Expert commentary on the origin and effective management of differentiation syndrome in patients with AML being treated with enasidenib
“Differentiation syndrome in [relapsed/refractory AML] does not predict for response, and that’s very important to know. It becomes tricky to figure out, ‘Is my patient who is having differentiation syndrome…going to respond? Is this leukocytosis that I’m seeing? Is this a harbinger of differentiation syndrome, or is this disease progression?’ We really need to study this more.”
 — Eytan M. Stein, MD

For additional commentary about these topics and others, visit www.gotoper.com to access more resources from the archived AML Year in Review™: Live Webcast Around the World.







Become a Member

Forgot Password?
Filter By